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below 1 cm3. Some TPS shows differences in volume 
calculation between contour and calculation modules (iPlan, 
Oncentra, Monaco) and Elekta Oncentra have the highest 
differences compared with the others TPSs. Monaco losses 
some very small structure (<0.3 cm3) when importing 
contours. In figure 1b it is shown minimum, maximum and 
mean differences of every TPS versus mean reference volume 




Conclusions: It is necessary to study and QA volume 
reconstruction algorithm of TPSs before starting an SRS/SBRT 
program. Specific tests for small volumes below 1 cm3 have 
to be made and developed. 
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Purpose/Objective: Acuros XB® is a recent advanced 
algorithm for photon dose calculation. Similarly to Monte 
Carlo simulations, AXB calculates doses using proper media 
cross section. The aim of this study was to investigate AXB 
capacity to correctly account for a virtual material 
assignment for patient QA in ArcCHECK® diode array (AK).  
Materials and Methods: Relative differences were estimated 
between calculations and measurements in function of the 
virtual material assigned to the AK. The following virtual 
materials were studied by scaling CT number to reach AK 
relative electron density or mass density: human tissues 
obtained by default on the phantom CT scan, physical 
material and water. In addition, Anisotropic Analytical 
Algorithm (AAA) and AXB results were compared. Parametric 
studies were done in isocentric conditions by varying scatter 
conditions. Prostate and endometrial patient treatment cases 
were studied in the AK using ionization chamber (IC), 
Gafchromic films and diodes measurements.  
Results: Regarding the open field tests, ionization chamber 
measurements at isocenter have shown relative differences 
of 1.5+/-0.3% using PMMA and -1.2+/-0.3% using the default 
material (cartilage) each time in combination with a scaled 
CT number to the AK's mass density. In the cases of water 
scaled to mass and relative electron density, results have 
been higher: -2.8+/-0.4% and -3.4+/-0.5%. Regarding the 
patient treatment studied cases, the best results for 
ionization measurements were obtained with AXB using the 
cartilage (with CT numbers adapted to mass density) and 
PMMA materials. No significant differences were obtained 
with diode pass rates. Gafchromic films have given 
interesting results and showed for prostate cancer treatment 
plans better dose estimation with PMMA material (figure 1). 
 
Conclusions: Phantom CT numbers have to be adjusted to 
mass density for advanced algorithms such as AXB and to 
relative electron density for conventional algorithms such as 
AAA. Better results are observed if right physical materials 
are applied to the virtual phantom images (PMMA for the 
ArcCHECK phantom). This study leads to state that a 
particular attention should be paid to QA phantom 
commissioning in the TPS for advanced algorithm such as 
AXB. 
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Purpose/Objective: Dysphagia is one of the most disabling 
complications associated with head-neck chemo-radiotherapy 
intensification. Pharyngeal constrictor muscles (PCM) and 
supraglottic larynx (SGL) have been identified as principal 
organs in which swallowing dysfunction after chemo-radiation 
causes dysphagia. If significant correlations between 
dysphagia and increased doses to PCM and SGL are now 
established, dose sparing of swallowing structures still 
represents a major challenge in HN planning optimization 
process. In this study, we explored the potential of VMAT 
technique to reduce the risk on swallowing problems after 
curative chemo-radiotherapy. 
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Materials and Methods: Eighteen head-and-neck cancer 
patients who previously underwent radiotherapy for the 
bilateral neck were selected. Radiotherapy was prescribed 
according to Simultaneous Integrated Boost technique with 
all PTVs irradiated simultaneously over 30 daily fractions. 
Doses of 70.5, 60.0 and 55.5 Gy were prescribed to CTV1 
(primary tumor), CTV2 (high-risk nodal regions) and CTV3 
(low-risk nodal regions). Clinical dual-arc VMAT plans (ST-
VMAT) were originally created with Masterplan Oncentra TPS. 
For each patient, a new plan (SW-VMAT) based on the 
approved ST-VMAT plan was created. PCM and SGL were 
considered OARs related to swallowing dysfunction (SW-
OARs). Upper (uPCM), middle (mPCM) and lower (lPCM) part 
of PCM were outlined separately. All objectives for PTVs 
coverage and non related swallowing OARs ((NSW-OARs: 
parotids, eyes, lens, optic chiasm, brainstem, optic nerves) 
sparing were left unchanged. New objectives were added for 
SW-OARs, with priority to minimize mean doses to uPCM and 
SGL. NTCP for physician-rated swallowing dysfunction was 
calculated using the recently predictive model by Christianen 
et al (MEMC Christianen et al. Radioth Oncol 105 (2012) 107–
114). The Wilcoxon signed-rank test was used to compare the 
two optimization techniques. 
Results: For all plans targets coverage was well within the 
predefined objectives, with at least 98% of PTVs receiving 
95% of prescribed doses. SW-VMAT plans showed slight 
increased dose inhomogeneity. No differences were found in 
sparing of parotid glands for ST-VMAT and SW-VMAT. No 
significant differences were found for all others NSW-OARs. 
For PCM and SGL, mean doses, V60 and V65 were lowest with 
SW-VMAT plans. Mean doses for uPCM and SGL were reduced 
by 3.7 Gy and 4.6 Gy, respectively; V60 decreased from 82% to 
65% for uPCM and from 63% to 46% for SGL. The mean 
reduction of NTCP-values for RTOG grade 2–4 swallowing 
dysfunction was 9.2% (range, 4.4–16.9%). Dose reductions 
with SW-VMAT widely varied among patients and depend on 
tumor location and overlap with SW-OARs (figure 1).  
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Conclusions: SW-VMAT plans aiming at sparing swallowing 
structures are feasible, with the potential to reduce NTCP 
swallowing dysfunction with respect to conventional ST-
VMAT.  
   
EP-1458   
Proton breast treatments: eclipse vs Monte Carlo Fluka 
dose comparison study  
F. Fiorini1, S. Hackett1, F. Van den Heuvel1 
1CRUK/MRC Oxford Institute for Radiation Oncology 
University of Oxford, Oncology, Oxford, United Kingdom  
 
Purpose/Objective: We present a Fluka Monte Carlo (MC) 
simulation study for proton treatments based on Varian 
Eclipse proton plans for left breast cancers including the 
internal mammary chain. Doses calculated in TPSs are usually 
accurate within the primary field, but less accurate outside. 
With the MC treatment verification we can not only find 
possible inaccuracies in the delivered dose to the regions of 
main interest (PTV and OAR like heart and left lung) mainly 
due to body inhomogeneities close to the PTV (i.e., ribs and 
lung), but also find the accurate dose deposited in other 
healthy tissues not included in the TPS optimisation (contra 
lateral lung, contra lateral breast). Doses deposited by other 
particles not generated in the TPS, but usually created during 
a real treatment, such as neutrons and light ions, are also 
accounded for in the MC. All of this allows us to more 
accurately determine toxicity to healthy tissues and risk of 
secondary malignancies. 
Materials and Methods: Before starting any comparison 
between the MC and the TPS, the virtual CAP GENERAL 
machine used in the proton Eclipse TPS had to be accurately 
characterised. In this context studies were performed using 
virtual water phantoms to determine the beam 
characteristics (energy, energy spread, spatial spread) and so 
to prove the equivalence of Eclipse plans in Fluka.  
Eighteen different patient plans for breast treatments were 
then performed using Eclipse and the information about the 
used beams included in the TPS RTPLAN files were extracted 
and converted to plans in Fluka. This allowed us to perform 
dose comparisons between plans and simulations in the entire 
upper body of the patient. 
Results: In this work we developed a method of performing 
treatment verification of Eclipse breast plans with the Monte 
Carlo Fluka and show that dose differences up to 4% in the 
PTV and up to 70% in other healthy tissues (i.e., contra 
lateral breast) can be observed when the TPS plans are 
compared with Fluka simulations of the same plans. 
Conclusions: While the Varian TPS for conventional 
radiotherapy is widely used, the proton Eclipse TPS is only 
used in a few facilities, resulting in a dearth of comparison 
studies. In particular breast treatments with protons are in 
the early stages of investigation and not many groups so far 
have demonstrated the accuracy of TPSs with respect to this 
treatment site. With this study we demonstrate that 
treatment verification with Monte Carlo simulations is 
essential to better determine the dose deposited in the 
entire patient body, and in particular to the healthy tissues.  
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Purpose/Objective: To perform a dosimetric evaluation of 
arc-based modulated electron radiation therapy (arc-MERT) 
using a direct aperture optimization (DAO) algorithm.  
Materials and Methods: An arc-MERT plan was mimicked by 
setting a series of field ports with small angle increments 
(between 6° and 15° depending on the case). When possible, 
a single isocenter was used for the field set-up; this was not 
always possible due to the short source-to-skin distance 
(~70cm) used for MERT planning using the photon MLC for 
beam collimation. For each field port, beamlet dose 
distributions were generated for several different electron 
beam energies. A treatment plan is created by selecting and 
optimizing the shape and the weight of a certain number of 
initial apertures per beam energy and per field. Thus, 
different combinations of apertures can be investigated with 
the available field ports and beam energies. This approach 
was applied for two clinically motivated situations: a head 
and neck and a breast case. For the head and neck case, 13 
field ports spanning a 140° arc were set up using multiple 
isocenters. For the breast case, 6 field ports spanning a 30° 
arc were set up using a single isocenter. For both cases, 
many plans were generated using different combinations of 
apertures (between 10 and 90 apertures per plan). The dose 
homogeneity to the PTV as well as the doses to organs at risk 
(OAR) were determined and compared to photon plans. 
Results: Using arc-MERT, it is possible to achieve a high dose 
homogeneity to the PTV (V95%-V107% > 95%), which is similar 
to the photon plan. Good treatment plans can already be 
achieved using between 30 to 50 apertures and more than 
one electron beam energy. For the head and neck case, the 
organs at risk sparing was similar to the original VMAT plan, 
while the low dose bath could be substantially reduced with 
arc-MERT (V10% = 554 cc versus 1150 cc for VMAT). For the 
breast case, the high dose homogeneity to the PTV achieved 
with arc-MERT came at the cost of high ipsilateral lung doses 
(mean dose 20 Gy, V30Gy = 34%). If the CTV had to be 
adequately covered instead of the PTV (defined for 
tangential photon plans), the doses to the ipsilateral lung 
could be substantially reduced (mean dose 7.3 Gy, 
V30Gy=1%). 
Conclusions: arc-MERT offers the potential to achieve high 
dose homogeneity to the PTV similar to photon plans and 
depending on the case also similar OAR sparing while 
reducing the low dose bath. More work is required to define 
which sites would most benefit from arc-MERT. This work is 
supported by the Swiss Cancer Research grant KFS-3279-08-
2013. 
    
 
 
 
 
 
 
